New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy

被引：0
|
作者：
Chacon, Aurelia [1 ]
Bobin, Arthur [1 ]
Leleu, Xavier [1 ]
机构：
[1] CHU Poitiers, Serv Oncohematol, 2 Rue Mil,Cs 90577, F-86000 Poitiers, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 10期
关键词：
Multiple myeloma; CAR T; Anti-BCMA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：993 / 995
页数：3
相关论文
共 50 条
  • [21] New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients
    van de Donk, Niels W. C. J.
    Lokhorst, Henk M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (12) : 1569 - 1573
  • [22] Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients
    Min, Chao
    Zhong, Xiong
    Cui, Yue
    Zhang, Hanfu
    Wang, Qingming
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [23] Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Sonneveld, Pieter
    Hajek, Roman
    Nagler, Arnon
    Spencer, Andrew
    Blade, Joan
    Robak, Tadeusz
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    CANCER, 2008, 112 (07) : 1529 - 1537
  • [24] Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
    Quach, Hang
    Nooka, Ajay
    Samoylova, Olga
    Venner, Christopher P.
    Kim, Kihyun
    Facon, Thierry
    Spencer, Andrew
    Usmani, Saad Z.
    Grosicki, Sebastian
    Suzuki, Kenshi
    Delimpasi, Sosana
    Weisel, Katja
    Obreja, Mihaela
    Zahlten-Kumeli, Anita
    Mateos, Maria-Victoria
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (04) : 784 - 788
  • [25] Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
    Cancanelli, Luca
    Rivano, Melania
    Di Spazio, Lorenzo
    Chiumente, Marco
    Mengato, Daniele
    Messori, Andrea
    HEMATOLOGY REPORTS, 2023, 15 (01) : 57 - 65
  • [26] Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience
    Trando, Aaron
    Ghamsari, Farid
    Yeung, Philip
    Costello, Caitlin
    Saunders, Ila
    Jeong, Ah-Reum
    BIOMEDICINES, 2025, 13 (01)
  • [27] A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
    Jung, Sung-Hoon
    Lee, Hyun-Ju
    Lee, Youn-Kyung
    Yang, Deok-Hwan
    Kim, Hyeoung-Joon
    Rhee, Joon Haeng
    Emmrich, Frank
    Lee, Je-Jung
    ONCOTARGET, 2017, 8 (25) : 41538 - 41548
  • [28] A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
    von Lilienfeld-Toal, Marie
    Hahn-Ast, Corinna
    Furkert, Kerstin
    Hoffmann, Florian
    Naumann, Ralph
    Bargou, Ralf
    Cook, Gordon
    Glasmacher, Axel
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (04) : 247 - 252
  • [29] Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
    Munshi, Nikhil
    Pavia, Bruno
    Martin, Thomas
    Usmani, Saad
    Lin, Yi
    Schecter, Jordan
    Jackson, Carolyn
    Madduri, Deepu
    Zudaire, Enrique
    Yeh, Tzu-Min
    Bartlett, J. Blake
    Pacaud, Lida
    Akram, Muhammad
    Geng, Dong
    Jagannath, Sundar
    Cohen, Adam
    San-Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S487 - S488
  • [30] Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients
    Frigault, Matthew
    Rosenblatt, Jacalyn
    Dhakal, Binod
    Raje, Noopur
    Cook, Daniella
    Gaballa, Mahmoud
    Emmanuel-Alejandro, Estelle
    Nissen, Danielle
    Banerjee, Kamalika
    Rotte, Anand
    Heery, Christopher
    Avigan, David
    Jakubowiak, Andrzej
    Bishop, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S553 - S553
12345